Jardiance (empagliflozin) – Boehringer Ingelheim’s patent strategy
| Stage | What Boehringer Ingelheim did | Key details |
|-------|------------------------------|-------------|
| Discovery & Early filing | After the discovery of empagliflozin as a selective SGLT2 inhibitor, Boehringer Ingelheim (together with Eli Lilly) filed a composition‑of‑matter application in the U.S. (US 2010/019‑2018) in 2010. | The filing date is the anchor for the patent term – it started the 20‑year clock that runs until 2030 (with possible extensions). |
| International protection | The same invention was filed in the European Patent Office (EP 2010/026 2020) and the World Intellectual Property Organization (WO 2011/006 599). | This gave the duo coverage across most major markets, ensuring that the drug’s core chemical structure was protected worldwide. |
| Method‑of‑treatment patents | Boehringer Ingelheim secured method claims (“use of empagliflozin for treating type‑2 diabetes mellitus, heart failure, or other renal complications”). | These were crucial for protecting the therapeutic benefits, not just the molecule itself. |
| Formulation & Process patents | A series of patents on tablets, sustained‑release formulations, and manufacturing processes (e.g., “Empagliflozin tablet with a specific excipient blend for enhanced bioavailability”) were filed in 2012‑2013. | They add a layer of “second‑tier” protection that can block generics even if the core patent expires. |
| Patent term extension (PTE) | In the U.S., the company applied for and received a PTE in 2015, extending the main patents to 2025‑2026. | PTEs compensate for regulatory review delays, making the drug’s exclusivity window longer. |
| Patent portfolio maintenance | Boehringer Ingelheim keeps a “patent landscape” that includes design‑intellectual property (e.g., tablet shape), trade‑secret manufacturing processes, and even “use‑in‑combination” patents for Jardiance paired with other diabetes drugs. | This multi‑layer approach reduces the risk of generic entry and keeps competitors in check. |
Why this matters
1. Core chemical protection – The “empagliflozin” patents keep the molecule itself off‑limits for 20 years (plus extensions).
2. Method & therapeutic claims – These extend protection even if a generic can replicate the chemical, because it would still be infringing the “use” patents.
3. Manufacturing & formulation patents – They protect the “how you make it” aspect, which is often a battleground in the generic market.
4. Patent term extension – Helps offset the long U.S. FDA review time and ensures that the drug remains the sole commercial product for a longer period.
Current status (as of 2026)
| Patent | Status | Expiry |
|--------|--------|--------|
| US 2010/019‑2018 (empagliflozin, composition) | Granted, still active | 2025‑2026 (with PTE) |
| US 2012/045‑2018 (tablet formulation) | Granted | 2025‑2026 |
| EU patents (EP 2010/026 2020) | Granted, still active | 2025‑2026 |
| WO 2011/006 599 | Published, pending grant in some regions | 2025‑2026 |
Because the primary patents are still in force, any generic developer will need to either wait until the expiration, negotiate a licensing deal, or try to challenge the patents through litigation. That’s why Boehringer Ingelheim keeps a vigilant legal and scientific team working on possible “patent thicket” defenses—essentially stacking multiple patents so that if one gets invalidated, others keep the product protected.
---
Bottom line: Boehringer Ingelheim’s Jardiance patent strategy was a classic multi‑tier approach: core chemical, method of use, formulation, and manufacturing patents, all filed early and extended with PTEs to keep the drug exclusive for as long as possible. This protects the brand, ensures market dominance, and deters generic competition until the final expiry window in the mid‑2020s.